Skip to Content

Join the 'Insulin Degludec / liraglutide' group to help and get support from people like you.

Insulin Degludec / liraglutide News

Native Americans Make Progress Against Diabetes Complication

Posted 11 days ago by Drugs.com

TUESDAY, Jan. 10, 2017 – Diabetes-related kidney failure among Native American adults fell by more than half over almost 20 years, a U.S. Centers for Disease Control and Prevention report shows. The change is due to improvements in diabetes and kidney care, according to the report. The new research also found that among these patients, blood sugar control improved 10 percent between 1996 and 2014, and the use of medicine to protect kidneys rose from 42 percent to 74 percent over 5 years. Average blood pressure in Native Americans with diabetes and high blood pressure was well controlled (133/76 in 2015), the findings showed. In addition, more than 60 percent of Native Americans aged 65 and older with diabetes had a urine test for kidney damage in 2015, compared with 40 percent of Medicare patients with diabetes in 2013, the researchers said. "The Indian Health Service (IHS) has made ... Read more

Related support groups: Diabetes, Type 2, Metformin, Insulin, Lantus, Renal Failure, Glucophage, Novolog, Glipizide, Humalog, Insulin Resistance, Janumet, Glyburide, Lantus Solostar, Levemir, Glimepiride, Pre-Diabetes, Chronic Kidney Disease, Novolin R, Amaryl, Novolin N

Novo Nordisk Receives FDA Approval for Xultophy 100/3.6 (insulin degludec and liraglutide injection)

Posted 22 Nov 2016 by Drugs.com

PLAINSBORO, N.J., Nov. 21, 2016 /PRNewswire/ – Novo Nordisk, a world leader in diabetes care, today announced that the U.S. Food and Drug Administration (FDA) approved the New Drug Application for Xultophy 100/3.6 (insulin degludec 100 units/mL and liraglutide 3.6 mg/mL injection). Xultophy 100/3.6 is a once-daily, combination of Tresiba (insulin degludec injection) and Victoza (liraglutide) injection indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes inadequately controlled on less than 50 units of basal insulin daily or less than or equal to 1.8 mg of liraglutide daily.1 Xultophy 100/3.6 enters into a new class of diabetes treatments that combine a basal insulin and a glucagon-like peptide-1 receptor agonist (GLP-1 RA) in a single, once-daily injection. "Novo Nordisk is committed to discovering and developing new medicines, like ... Read more

Related support groups: Diabetes, Type 2, Victoza, Liraglutide, Insulin Degludec, Tresiba, Xultophy 100/3.6, Insulin Degludec/liraglutide

Ask a Question

Further Information

Related Condition Support Groups

Diabetes, Type 2

Related Drug Support Groups

Xultophy 100 / 3.6